Blue Jet Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Blue Jet Healthcare reported H1 FY26 (six months ended Sep 30, 2025) revenue of ₹520.24 crore, up about 40% YoY from ₹371.16 crore. Net profit for H1 FY26 rose roughly 49% YoY (Basic EPS of ₹8.26 vs ₹5.54), with profit before tax of ₹191.59 crore versus ₹126.39 crore. However, the Q2 FY26 (three-month) picture was weaker, with standalone revenue of ₹165.48 crore declining about 20.5% YoY from ₹208.26 crore, reflecting a sharp pullback from the unusually strong Q1 FY26 base of ₹354.76 crore. Operating cash flow jumped to ₹207.19 crore from ₹62.06 crore in H1 FY25, and the company is investing heavily with ₹125.47 crore in capex and capital work-in-progress rising to ₹158.76 crore from ₹88.88 crore. Auditor KKC & Associates issued an unqualified limited review report with no qualifications or emphasis-of-matter paragraphs.
Strong half-year growth is tempered by a sharp Q2 YoY revenue decline, which could worry investors about demand normalisation after a strong Q1. Healthy cash generation and rising capex suggest management is betting on capacity-led growth, but the Q2 softness may cap near-term upside in the stock.